Safety of arthritis drug under scrutiny after blood clots reported
The European Medicines Agency (EMA) is advising prescribers not to exceed the recommended dose of Xeljanz (tofacitinib) when treating RA after early results from an ongoing trial showed an increased risk of pulmonary embolism and all-cause mortality when the normal dose was doubled.
by Lisa Lytle
To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.